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A B S T R A C T
Purpose: To determine the outcomes in regards to seizure control and foetal malformation in pregnant
women with epilepsy not treated with antiepileptic drugs (AEDs).
Method: Analysis of data from the Australian Register of AEDs in Pregnancy on 148 women with epilepsy
who were not receiving AEDs before and during at least the ﬁrst trimester of pregnancy.
Results: Seizure control was less likely to be maintained in AED-untreated pregnancies. Whether AED
therapy had been ceased in preparation for pregnancy, or had not been employed for long periods before
pregnancy, made no statistically signiﬁcant difference to seizure control outcomes, but those who ceased
therapy in preparation for pregnancy were more likely to again be taking AED therapy by term.
Foetal malformation rates were reasonably similar in untreated pregnancies, and in treated
pregnancies if pregnancies exposed to known AED teratogens (valproate and probably topiramate) were
excluded from consideration.
Conclusion: Leaving epilepsy untreated during pregnancy appears disadvantageous from the standpoint
of seizure control: it also does not reduce the hazard of foetal malformation unless it avoids valproate or
topiramate intake during pregnancy.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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The extensive and continuing publicity regarding the foetal
malformations associated with the use thalidomide by pregnant
women in the 1960s made many women aware of the hazards of
therapeutic drug intake during pregnancy. This wariness extends
to antiepileptic drugs (AEDs), even though most women with
epilepsy also appreciate the importance of maintaining optimal
freedom from their seizures. Prior to undertaking pregnancy some
women with epilepsy consider ceasing their AED therapy. Some
may seek medical advice regarding the advantages and disadvan-
tages of doing so. Others make their own unguided decisions and
either reduce dosages on their own initiative or cease AEDs
altogether.1 However, there is relatively little information as to
what actually happens to women with epilepsy who enter
pregnancy when not taking any AED therapy.
The Australian Register of Antiepileptic Drugs in Pregnancy is
concerned mainly with teratogenesis issues, but contains data on
the behaviour during pregnancy of the seizure disorders of those
enrolled in it. Some 8.8% of the pregnancies in women with* Corresponding author. Tel.: +61 398193056; fax: +61 393428628.
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months of pregnancy. Some were not exposed throughout
pregnancy. We here compared what happened to the pregnancies
of these untreated women with what happened to the pregnancies
exposed to AED therapy throughout.
2. Materials and methods
2.1. The Australian Pregnancy Register
The nature of the Australian Register of Antiepileptic Drugs in
Pregnancy and its method of data collection and storage have been
described previously.2–4 The Register, which has been collecting
data since 1999, is estimated to have captured some 8 to 9% of all
Australian pregnancies in women with epilepsy.5 In essence, the
Register has functioned by enrolling pregnant women, the great
majority of whom had epilepsy and took AEDs, and prospectively
following the outcomes of their pregnancies. These women
initiated their own participation in the Register’s database once
they had become aware of its existence. All contact between the
women and the Register was by means of telephone, with
interviews on 4 occasions – at recruitment as early in pregnancy
as feasible, at 7 months of gestation, in the post-partum month
and, as far as possible, one year after childbirth. At each interview,served.
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patient’s epilepsy, and of the occurrence and type of any epileptic
seizures and the antiepileptic drugs being taken and their dosages,
were recorded. Women taking AEDs for a non-epileptic indication
are also enrolled on the Register, however for the present paper
only women with epilepsy were studied, whether or not they were
taking AEDs during the earlier months of pregnancy.
Ethical oversight of the Register has been the responsibility of
the Ethics Research Committees of St. Vincent’s Hospital,
Melbourne, the Monash Medical Centre, and the Royal Melbourne
Hospital, because the Register’s site of housing has changed with
time.
2.2. Data analysis
Data were exported from the Register’s database into an Excel
spreadsheet for further analysis, and statistical signiﬁcances
assessed by means of conﬁdence interval analysis.
In the analyses, a distinction was made between the outcomes
for seizure control during pregnancy in women with ‘active’ and
with ‘inactive’ epilepsy, i.e. in women who had, and women who
had not experienced seizures during the previous 12 months. It had
been observed previously that the prognosis for seizure freedom
during pregnancy was quite different, depending on whether or
not a woman had suffered seizures during her pre-pregnancy
year.6–8 In the present series, seizures had occurred during
pregnancy in 79.2% of pregnancies associated with less than 1 year
of pre-pregnancy seizure freedom, but in progressively lower
proportions of those with longer periods of seizure freedomTable 1
Characteristics of the untreated and AED treated pregnant women with epilepsy, their ep
various items occurring is expressed relative to that for the treated women.
No AEDS P < .0
Number 148 
Mean Age (years) 30.74 
Referral source – neurologist 51.4% 
Referral source – other medical practitioner 12.2% 
Pregnancy number – 1 46.6% 
Pregnancy number – 2 32.4% 
Pregnancy number – 3 11.5% 
Pregnancy number – 4 6.1% 
Pregnancy number – >4 3.4% 
Pregnancies 1 and 2 combined 79.1% > 
Assisted fertilisation involved 5.4% 
Previous malformed offspring (N = 79, 894) 2.5% 
Previous neonatal deaths (N = 79, 894) 1.3% 
Epilepsy duration (mean in years) 12.3 < 
Epilepsy type – partial 44.6% 
Epilepsy type – generalised 45.9% 
Epilepsy type – uncertain 9.5% 
AED change before pregnancy 41.9% > 
Preconception folate intake 65.5% < 
Seizures during pregnancy – any 56.1% > 
Seizures during pregnancy – convulsive 24.3% 
Active epilepsy before pregnancy 50.0% 
Seizures during pregnancy – any 82.4% 
Seizures during pregnancy – convulsive 36.5% 
Seizures during birth 2.7% 
Inactive epilepsy before pregnancy 50.0% 
Seizures during pregnancy – any 29.7% 
Seizures during pregnancy – convulsive 12.2% 
Seizures during birth 3.4% 
Malformed foetus 3.4% 
Malformed foetusb 3.4% 
Malformed foetusc 3.4% < 
a A difference, not a R.R. value.
b Pregnancies exposed to VPA and TPM excluded.
c Pregnancies exposed to VPA or TPM.(in 23% of those with at least 1 year’s freedom, in 20.5% with
2 years’ freedom, in 19% with 3 years’ freedom, in 17.5%
with 4 years’ freedom and in 17.7% with 5 or more years
seizure-freedom).
3. Results
Of 1720 pregnancies in women with epilepsy included in the
Australian Register, 148 (8.8%) were not exposed to AEDs at the
time of conception. Various characteristics of the pre-pregnancy
circumstances and the pregnancies, and the associated seizure
disorders in the AED untreated and AED treated groups, are
compared in Table 1. In general, the two groups seemed
reasonably similar in composition in relation to the parameters
considered. However, the AED treatment in the untreated group
had been changed more often before pregnancy than in the treated
group (because by deﬁnition being in the untreated group itself
often involved a treatment change, viz. withdrawal of therapy).
Members of the untreated group were more likely to have
experienced epileptic seizures of any type during pregnancy
(56.1% versus 46.9%). There were no statistically signiﬁcant
differences between the types of seizure disorder involved, the
occurrence rates of convulsive seizures at some stage during
pregnancy, and of the behaviours of active and inactive epilepsies.
Those not taking antiepileptic drugs were also less likely to have
taken folate before pregnancy. Foetal malformations were half
as frequent in the untreated group as in the AED treated
pregnancies, but the difference was not statistically signiﬁcant.
When pregnancies associated with continuing intake of valproateilepsies and foetal outcomes as far as malformation was concerned. The likelihood of
5 AEDs R.R. or Difference 95% C.I.
1532
30.69 0.05a 1.02, +1.12
47.9% 1.07 0.91, 1.26
15.9% 0.77 0.49, 1.20
41.6% 1.12 0.93, 1.34
29.6% 1.09 0.86, 1.40
16.1% 0.71 0.45, 1.49
7.1% 0.85 0.44, 1.65
5.4% 0.62 0.25, 1.49
73.1% 1.11 1.01,1.21
5.8% 0.93 0.43, 1.68
4.8% 0.53 0.13, 2.13
0.8% 1.62 0.20, 12.97
14.1 1.80a 3.25, 0.35
49.0% 0.91 0.76, 1.10
42.5% 1.08 0.90, 1.30
8.6% 1.11 0.65, 1.07
14.2% 3.03 2.42, 3.79
70.8% 0.85 0.75, 0.98
46.9% 1.20 1.03, 1.39
18.9% 1.29 0.95, 1.74)
43.6% 1.15 0.97, 1.36
79.1% 1.04 0.93, 1.16
32.8% 1.13 0.81, 1.53
3.6% 0.75 0.18, 3.12
56.4% 0.89 0.75, 1.05
21.9% 1.36 0.94,1.97
8.2% 1.48 0.77, 2.84
0.9% 2.92 0.63, 13.50
7.1% 0.47 0.20, 1.15
4.5% 0.74 0.30, 1.84
12.1% 0.28 0.11, 0.68
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little difference in the rate of foetal malformations between the
AED treated and untreated pregnancies. On the other hand, in
comparison with pregnancies exposed to valproate and/or
topiramate, the risk of foetal malformation was statistically
signiﬁcantly lower in the untreated pregnancies.
Within the 148 pregnancies not treated with AEDs at the time of
conception a number of features, mainly concerning seizure
activity, were compared between the women whose seizure
disorders were active before pregnancy and those whose disorders
were inactive (Table 2). The only signiﬁcant difference between
the two groups was a considerably higher rate of seizure
occurrence during pregnancy in the women with already active
epilepsies at entry into pregnancy (any seizures: 82.4% versus
29.7%; convulsive seizures: 36.5% versus 12.2%). The epilepsy
history for women who had active epilepsy before their untreated
pregnancies were of shorter mean duration (10.6 versus
14.1 years), and by term were more often being treated with
AEDs (55.4% versus 37.8%).
There were 62 of the 148 pregnancies (41.9%) in women who
had elected to cease AED treatment shortly prior to pregnancy.Table 2
Comparisons between women with active and inactive epilepsies that were not treate
occurring in the active epilepsy group is expressed relative to that for the women with
Active Epilepsy P < .05 
Number 74 
Mean Age (years) 30.1 
Referral source – neurologist 54.1% 
Referral source – other medical 16.2% 
Pregnancy numbers – 1 or 2 78.4% 
Pre-conception folate intake 59.5% 
Epilepsy – partial 47.3% 
Epilepsy – generalised 41.9% 
Epilepsy – type uncertain 10.8% 
Epilepsy duration (mean in years) 10.6 < 
Seizures during pregnancy – any 82.4% > 
Seizures during pregnancy – convulsive 36.5% > 
Seizures during birth 2.7% 
Taking AEDs by 7 months 53.1% > 
Taking AEDs by term 55.4% > 
Taking AEDs by term – had seizures 51.2% 
Foetal Malformations 2.7% 
a A difference, not a RR.
Table 3
Comparison of various differences between women who ceased AEDs in preparation for 
pregnancy.
Came off AEDS P
Number 62 
Mean Age (years) 29.7 <
Referral source – neurologist 51.6% 
Referral source – other medical 9.7% 
Pregnancy numbers – 1 or 2 82.3% 
Pre-conception folate intake 72.6% 
Pre-pregnancy active epilepsy 45.2% 
Epilepsy – partial 45.2% 
Epilepsy – generalised 43.55% 
Epilepsy – type uncertain 11.35% 
Epilepsy duration (mean, in years) 12.9 
Seizures during pregnancy – any 48.4% 
Seizures during pregnancy – convulsive 21.0% 
Seizures during birth 3.2% 
Taking AEDs by 7 months 43.5% 
Taking AEDs by term 56.4% >
Taking AEDs by term – had pregnancy seizures 83.3% >
Taking AEDs by term – no pregnancy seizures 31.3% 
Foetal Malformations 1.6% 
a A difference, not a RR.Nearly all of these women indicated that they wished to avoid drug
intake during pregnancy. The remaining untreated pregnancies
were in women with epilepsy that was either previously untreated
or in whom treatment had been ceased well before pregnancy. Half
of the women who were untreated in the longer term had
undergone previous pregnancies. Only four of these 43 (9.3%) had
taken AEDs in previous pregnancies. This suggested that there was
a group of women who followed a consistent pattern of reluctance
to take AEDs. The outcomes of the two subsets of untreated
pregnancies are compared in Table 3.
Those who deliberately ceased AED treatment in preparation
for pregnancy had a slightly younger mean age than those who had
been untreated over longer periods. There were no signiﬁcant
differences between the rates of occurrence of the major types of
seizure disorder in two groups, or in the proportions of each group
who had seizures during pregnancy. More who had ceased
treatment as a pre-pregnancy precaution were found to have
resumed AED therapy by the end of pregnancy (56.4% versus
39.5%). The data suggested that having seizures during pregnancy
in those who had ceased AEDs before pregnancy increased the
likelihood that AED therapy would be resumed by the end ofd with AEDs, at least in earlier pregnancy. The likelihood (R.R.) of various items
 inactive epilepsies.
Inactive Epilepsy R.R or Difference 95% C.I.
74
31.4 1.30a 2.85, 0.25
48.6% 1.11 0.81, 1.52
8.1% 2.00 0.79, 5.05
79.7% 0.98 0.83, 1.16
74.3% 0.80 0.64, 1.01
41.9% 1.13 0.79, 1.62
50.0% 0.84 0.59, 1.19
8.3% 1.30 0.47, 3.55
14.1 3.50a 6.54, +0.46
29.7% 4.00 2.39, 6.70
12.2% 3.00 1.52, 5.93
2.7% 1.00 0.14, 6.91
29.7% 1.79 1.18, 2.72
37.8% 1.46 1.03, 2.09
57.1.4% 0.90 0.58, 1.39
4.1% 0.67 0.11, 3.87
pregnancy, and those who were not taking AEDs well before the commencement of
 < .05 Not on AEDS R.R. or Difference 95% C.I.
86
 31.5 1.80a 3.36, 0.24
51.2% 1.01 0.73, 1.39
14.0% 0.69 0.28, 1.75
76.7% 1.07 0.91, 1.26
60.5% 1.20 0.95, 1.51
47.7% 0.95 0.67, 1.35
44.2% 1.02 0.71, 1.47
47.6% 0.91 0.64, 1.31
3.5% 3.24 0.87, 12.03
11.9 +0.9a 2.23, +4.03
61.6% 0.79 0.58, 1.07
26.7% 0.78 0.43, 1.42
2.3% 1.39 0.20, 9.58
35.7% 1.29 0.86, 1.95
 39.5% 1.43 1.02, 2.01
 54.7% 1.52 1.14, 2.04
15.2% 2.06 0.79, 5.37
4.7% 0.35 0.04, 3.03
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The same applied for those with longer term non-use of AEDs
(54.7% v 15.2%; R.R. = 3.61, 95% C.I. = 1.55, 8.40).
Foetal malformation rates were too low to permit conclusions
regarding differences in teratogenesis hazard between the two
patterns of untreated pregnancies, or between treated and
untreated pregnancies if the effects of valproate and topiramate
exposure, as mentioned above, were excluded
4. Discussion
Since the review of Schmidt10 more than 30 years ago, a
number of papers have been published concerning the effects
of pregnancy on epileptic seizure control (e.g. 7), but almost all
of these apply to AED-treated epilepsy. There is a paucity of
quantitative data on untreated epilepsy in pregnancy that can be
compared with the ﬁndings of the present study. So long as it is
accepted that AEDs can prevent epileptic seizures, some
outcomes of the study described are as expected, e.g. that
those who were not taking AEDs at the outset of pregnancy
would be more likely to have seizures during pregnancy than
those who had similar degrees of seizure activity before
pregnancy but continued to take AEDs. It might also have been
anticipated that there would have been more difference than
was found in the rates of seizure occurrence in pregnancy
between those who had recently ceased antiepileptic drug
treatment in anticipation of pregnancy and those who had
not taken antiepileptic drugs for a longer time, if ever.
The number of untreated pregnancies in the present study is
comparatively small, relative to the number of treated pregnan-
cies, though this represents the outcome of 15 years of nationwide
voluntary data collection. To delay analysis till sufﬁcient numbers
had been accumulated to signiﬁcantly increase the statistical
power of the study would probably involve a prohibitively long
period during which therapeutic practice might change. Because of
comparatively small numbers in the untreated group, failure to
detect statistically signiﬁcant differences in some parameters
studied may not necessarily mean that real differences do not exist,
particularly when relative risk values are near a 95% conﬁdence
interval limit. Thus there was a statistically signiﬁcant increase risk
of any type of seizure occurring during pregnancy in the untreated
group (relative risk 1.20; 95% conﬁdence interval 1.03, 1.39).
However in the component subsets of this group, one where
seizures had occurred in the year before pregnancy and the other
where they had not occurred, the differences did not achieve
statistical signiﬁcance. It is also possible that in some of the
pregnancies that fell into the treated category, the women involved
may not have been fully compliant with prescribed therapy. If so,
this may have decreased the true differences in seizure occurrence
rates between the untreated and treated groups, when the rates in
the untreated group already tended to be higher.
The chance of having seizure during childbirth was very similar
for women who had been seizure free compared with those who
had not been seizure free in the year prior to pregnancy. The
chances were also little different in women who had ceased
antiepileptic drug intake for pregnancy and those who had not
been taking the drugs well before the onset of pregnancy. However,
the interpretation of these ﬁndings is confounded by the fact that
more women with active epilepsies before pregnancy, and those
who ceased the drugs intending to become pregnant, had resumed
the drugs before childbirth.
It appeared that the main determinant of the outcome
regarding seizure occurrence in AED-untreated pregnancy was
not so much the length of time before pregnancy over which no
AED treatment was taken, but whether the women’s epilepsy
was active or inactive when they entered pregnancy. If the epilepsywas active, women would probably tend to experience further
seizures during pregnancy so that the disadvantages and hazards
that they were already experiencing would continue. If the
epilepsy prior to pregnancy was inactive, the women seemed to
have less risk of having seizures during pregnancy than the
women whose pre-pregnancy epilepsy was active. However, the
women with inactive epilepsy still had about a 30% risk of seizures
in pregnancy. This risk appeared greater, though not statistically
signiﬁcantly so, than the risk of seizures returning in pregnancy in
the women with inactive pre-pregnancy epilepsy who continued
to take antiepileptic medication in pregnancy. The untreated
women with inactive epilepsy would probably have proportion-
ately more to lose from having their seizures recur during
pregnancy than the women with already active epilepsy, since
the former would then face additional disadvantages, including the
possibilities of physical injury during seizures, and possible sudden
unexpected death, and would also have restrictions imposed on
their lifestyle activities, including vehicle driving.
In conclusion the experience of the present series suggested
that while ceasing AEDs that are known teratogens, such valproate
and possibly topiramate, in anticipation of pregnancy may
decrease the risk of having a foetal malformation, for the less
teratogenic medication the risk to the foetus of continuing the
medication may be positively outweighed by the improvement
in seizures control for the mother. This is particularly true for
women whose epilepsy was active in the year prior to the
pregnancy. This information may help inform women with
epilepsy weighing up the risks and beneﬁts of withdrawal of
AED therapy in preparation for pregnancy.
Conﬂict of interest statement
None of the authors has any conﬂict of interest to disclose.
Acknowledgments
We wish to acknowledge the help of our medical and non-
medical colleagues, both in referring patients and in increasing
patient awareness of the Register. We thank the Scientiﬁc Advisory
Board and the Ethical Research Committees of St. Vincent’s
Hospital, Monash Medical Centre, the Royal Melbourne Hospital
and other institutions for their ethics assessments of the study. The
Australian Register is grateful for support from the Epilepsy Society
of Australia, The Victorian Epilepsy Foundation, Epilepsy Australia
and for ﬁnancial support from a number of pharmaceutical
companies, including Sanoﬁ-Aventis, UCB Pharma, Janssen-Cilag,
Novartis, and Sci-Gen.
References
1. Williams J, Myson V, Steward S, Jones G, Wilson JF, Kerr MP, et al. Self-
discontinuation of antiepileptic medication in pregnancy: detection by hair
analysis. Epilepsia 2002;43:824–31.
2. Vajda F, O’Brien T, Hitchcock A, Graham J, Lander C, Eadie M. The Australian
pregnancy register of antiepileptic drugs – aspects of data collection and
analysis. J Clin Neurosci 2007;14:936–42.
3. Vajda FJE, Hollingworth S, Graham J, Hitchcock AA, O’Brien TJ, Lander CM, et al.
Changing patterns of antiepileptic drug use in pregnant Australian women. Acta
Neurol Scand 2010;121:89–93.
4. Vajda FJE, O’Brien TJ, Lander CM, Eadie MJ. The rationale for pregnancy registers
for women with epilepsy. Med J Aust 2011;195:8–9.
5. Vajda FJE, O’Brien TJ, Graham J, Lander CM, Eadie MJ. The Australian register of
antiepileptic drugs in pregnancy: changes with time in its epileptic population. J
Clin Neurosci 2014;21:1478–82.
6. Vajda FJE, Hirchcock A, Graham J, O’Brien T, Lander C, Eadie M. Seizure control in
antiepileptic drug-treated pregnancy. Epilepsia 2008;49:172–5.
7. Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Hauser WA, et al. Manage-
ment issues in women with epilepsy – focus on pregnancy (an evidence-based
review): I. Obstetrical complications and changes in seizure frequency. Epilepsia
2009;50:1229–36.
F.J.E. Vajda et al. / Seizure 24 (2015) 77–81 818. Reisinger TL, Newman L, Loring W, Pennell PB, Meador KJ. Antiepileptic drug
clearance and seizure frequency during pregnancy in women with epilepsy.
Epilepsy Behav 2013;29:13–8.
9. Vajda FJE, O’Brien TJ, Graham J, Lander CM, Eadie MJ. Associations
between particular types of foetal malformation and antiepileptic drugexposure in utero. Acta Neurol Scand 2013;128:228–34. http://dx.doi.org/
10.1111/ane.12115.
10. Schmidt D. The effect of pregnancy on the natural history of epilepsy: review of
the literature. In: Janz D, Bossi L, Dam M, Helge H, Richens A, Schmidt D, editors.
Epilepsy, pregnancy, and the child. New York: Raven Press; 1982. p. 3–14.
